The European Union will buy a limited batch of "Remesivir" from Gilead to meet the short-term needs of European patients, and hopes to be able to order even more later. It is currently the only drug allowed in Europe for the treatment of patients with severe form of COVID-19, but almost all of Gilead's delivery options are already reserved by the USA. The EU will pay β¬63 million to buy enough for 30,000 patients.
The European Union will buy a limited batch of "Remesivir" from Gilead to meet the short-term needs of European patients, and hopes to be able to order even more later. It is currently the only drug allowed in Europe for the treatment of patients with severe form of COVID-19, but almost all of Gilead's delivery options are already reserved by the USA. The EU will pay β¬63 million to buy enough for 30,000 patients. 
uk.reuters.com
English (US) 